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Abstract
Background: Extended spectrum β-lactamase (ESBL) producing Enterobacteriaceae infections are associated with
delayed initiation of appropriate treatment, poor outcomes and increased hospital stay and expense. Although
initially associated with healthcare settings, more recent international reports have shown increasing isolation of
ESBLs in the community. Both hospital and community ESBL epidemiology in Ireland are poorly defined.
Methods: This report describes clinical and laboratory data from three hospitals over 4.5 years. All significant
isolates of Enterobacteriaceae were subjected to standardized antimicrobial susceptibility testing and screening for
ESBL production. Available patient data from hospital databases were reviewed.
Results: The database included 974 ESBL producing organisms from 464 patients. Urine and blood isolates
represented 84% and 3% of isolates respectively. E. coli predominated (90.9%) followed by K. pneumoniae (5.6%).
The majority of patients (n = 246, 53.0%) had been admitted to at least one of the study hospitals in the year prior
to first isolation of ESBL. The overall 30-day all-cause mortality from the date of culture positivity was 9.7% and the
1 year mortality was 61.4%. A Cox regression analysis showed age over 60, male gender and previous hospital
admissions were significant risk factors for death within 30 days of ESBL isolation. Numbers of ESBL-producing
E. coli isolated from urine and blood cultures increased during the study. Urine isolates were more susceptible than
blood isolates. Co-resistance to other classes of antimicrobial agents was more common in ESBL producers from
residents of long stay facilities (LSF) compared with hospital inpatients who lived at home.
Conclusions: This work demonstrates a progressively increasing prevalence of ESBL Enterobacteriaceae in hospital,
LSF and community specimens in a defined catchment area over a long time period . These results will improve
clinician awareness of this problem and guide the development of empiric antimicrobial regimens for community
acquired bloodstream and urinary tract infections.
Background
Since the first report of a plasmid-encoded extended
spectrum β-lactamase (ESBL) producing Enterobacteria-
ceae in 1983 [1], ESBLs have continued to increase in
variety and prevalence and are now a global health con-
cern. The spread of ESBLs has implications for clinicians
and patients as ESBLs have been associated with delays in
effective treatment [2], poor outcomes [3,4] increases in
hospital stay [5] and health care costs [6,7]. ESBLs are
commonly resistant to other antimicrobial agents because
of mobile genetic elements encoding other antimicrobial
resistance determinants and/or chromosomal mutations.
The co-resistance to other agents reduces the antimicro-
bial treatment options available and may enable selection
for ESBLs by non-beta-lactam antimicrobials such as the
aminoglycosides and fluoroquinolones.
While traditionally associated with healthcare settings,
more recent reports have shown increasing isolation of
ESBLs in the community setting [8]. Nursing homes and
other long stay facilities have been proposed as a reser-
voir for ESBLs in the community [9-11]. The residents
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often have risk factors for ESBL acquisition such as anti-
microbial exposure, prior hospital admission, incontin-
ence, urinary catheters and decubitus ulcers. In the UK
and Ireland, CTX-M enzyme producing organisms in
the community have emerged as a serious problem [12]
and have been associated with increasing resistance rates
to other antimicrobial agents [13].
The first report of an ESBL in Ireland was of an out-
break of Klebsiella pneumoniae in a paediatric hospital
in 1998 [14]. Subsequent assessments of ESBL epidemi-
ology in Ireland have been limited to small numbers of
isolates. The most comprehensive data on ESBL preva-
lence in Ireland to date is from the European Antimi-
crobial Resistance Surveillance System (EARSS). This
surveillance, which is limited to blood culture isolates
shows an increase in the prevalence of ESBL amongst
E. coli from 1.2% in 2002 to 5% in 2008 [15]. With re-
spect to isolates from other sites NíChulain et al. [16]
reported a prevalence of 0.3% amongst E. coli from urine
samples (hospital and community) from the West of Ire-
land in the period 2002–2003. Two of these ESBL
isolates were from the community. Cefotaximase-
producing (CTX-M) E. coli were first reported from Ire-
land in 2005 [17] and were associated with a long stay
facility (LSF) outbreak soon afterwards in 2006 [18]. To
date there has been no comprehensive longitudinal re-
port of ESBL prevalence from all clinical specimen types
from Ireland.
The objective of this report is to describe the changing
prevalence of ESBLs from all clinical sites in the hospital
and community over a period of 4.5 years. The data clar-
ify the extent of dissemination of ESBLs in the hospital
and community and should inform clinical and public
health awareness of this growing problem.
Methods
Setting
Galway University Hospitals (GUH: University College
Hospital Galway (UCHG) and Merlin Park Hospital) and
Roscommon County Hospital have a combined total of
1052 inpatient beds and about 44,000 admissions per
year. They are the major hospital service providers for
counties Roscommon and Galway in the west of Ireland.
The Clinical Microbiology service at GUH serves these
hospitals, approximately 90 nursing homes and General
Practitioners in much of Galway, Roscommon and parts
of Mayo. The population of these 3 counties in 2006 was
341,863 (www.cso.ie).
Bacterial isolates
All hospital and community isolates of Enterobacteria-
ceae cultured from clinical samples between July 2004
and December 2008 were screened for ESBL production.
Isolates from surface swabs, stool samples and rectal
swabs were excluded. Organisms were identified based
on colonial morphology on Chromagar and confirmed
with the VITEK-2W (bioMérieux, France). Throughout
the period routine susceptibility testing was performed
by the disc diffusion method of the Clinical Laboratory
Standards Institute (CLSI, formerly NCCLS) with sup-
plementary determination of MIC with Etest [19,20].
Routine quality control was performed with appropriate
strains as specified in CLSI documents. All significant
urine isolates (>100,000 CFU/ml pure culture) of Entero-
baceriaceae that were resistant to ampicillin were also
tested for susceptibility to coamoxiclav, ciprofloxacin,
trimethoprim, nitrofurantoin, cephalothin, cefuroxime,
cefotaxime, ceftazidime, piperacillin/tazobactam, nali-
dixic acid, ofloxacin, nalidixic acid, gentamicin, and ami-
kacin. All significant Enterobacteriaceae from sites other
than urine were tested for susceptibility to ampicillin,
coamoxiclav, cephalothin, cefuroxime, cefotaxime, cefta-
zidime, piperacillin/tazobactam, meropenem, nalidixic
acid, ciprofloxacin, gentamicin and amikacin.
From July 2004 to end of March 2005 ESBLs were identi-
fied based on the then current NCCLS criteria for screening
for ESBLs with cefotaxime (zone diameter ≤27 mm) and
cefuroxime (zone diameter ≤22 mm). From April 2005 to
December 2008 first line susceptibility testing of all urinary
Enterobacteriaceae was expanded to include cefpodoxime
to increase sensitivity of ESBL detection. Suspect ESBLs
were evaluated with cefpodoxime and cefpodoxime/clavula-
nate discs (Mast UK) by CLSI criteria confirmed with ESBL
EtestsW strips according to the manufacturer’s instructions
(AB Biodisk, Solna, Sweden).
Patient data
Galway University Hospitals and Roscommon County
Hospital share a networked patient and laboratory infor-
mation system. Data on all ESBL isolates were extracted
and manually cross-referenced between the laboratory
and hospital databases. For each patient the request date,
date of admission, time from admission to culture, date
of discharge, 30 day mortality, 1 year mortality, date of
death, admission to any of the three hospitals in the pre-
vious year, hospital number, specimen number, specimen
type, patient name, date of birth, clinician name, location,
hospital code, patient address and age were recorded.
Permission for the study was granted by the Director of
Pathology. Ethical permission was granted by the head of
the hospital ethics committee.
Statistical analyses
For all analysis except the comparison with the EARSS
data, only the first isolate was included for each patient. To
compare the prevalence of resistance between community
patients (i.e. patients not in hospital or a LSF at time of iso-
lation), hospitalised inpatients and LSF residents, a X2 for
Fennell et al. BMC Infectious Diseases 2012, 12:116 Page 2 of 8
http://www.biomedcentral.com/1471-2334/12/116
trend was performed. For analyses over time and for pur-
poses of comparison with EARSS data, quarterly results
were calculated in which only one isolate per patient per
quarter was counted. The results were plotted and a simple
linear regression line was calculated. Survival times were
calculated from the date of isolation of the ESBL by the la-
boratory to the date of death. Patients still alive at the end
of the study or of whom the outcome was uncertain were
censored and the survival time was calculated based on the
final date of the study. A Cox regression analysis using
backward conditional regression was done using the num-
ber of days between the detection of the ESBL and either
death or survival up to the first of June 2009 was counted.
The model produces a survival function that predicts the
probability of death at a given time t for given values of the
predictor variables. Predictor variables entered in the model
were age, residence in a nursing home, E.coli or other iso-
late, gender and admission to hospital in the year previous
to the detection of the ESBL. The resulting hazard ratios
and their 95% confidence interval can be compared with
(and interpreted as) an odds ratio obtained from a logistic
regression. The hazard ratio obtained from the Cox regres-
sion analysis adjusts each variable for the confounding ef-
fect of the others. Interaction between the variables was
checked but not found to be significant. Two models were
checked, the first assuming all patients of whom no further
records were found, were still alive at the end of the study
period, the second one excluding the patients of whom no
certainty was obtained concerning their status. Both models
showed the same outcomes and only the first is presented
here. All analyses were done with SPSS for Windows ver-
sion 18.0. The p-value for significance was set at 0.05.
Results
Over the 4.5 year period 974 ESBL isolates were cultured
from all sites from 464 patients. Of these patients 304
(65.5%) were female, 391 (84.3%) isolates were from
urine, 29 (6.3%) sputum and 16 (3.5%) from blood cul-
tures. Considering the first isolate per patient (n = 464)
E. coli was the predominant species (422, 91.0%) fol-
lowed by Klebsiella pneumoniae (26, 5.6%), Enterobacter
species (10, 2.2%) and the remaining isolates consisting
of Morganella morganii (3, 0.6%), Citrobacter freundii
(2, 0.4%) and Proteus mirabilis (1, 0.2%). The majority of
patients (n = 246, 53.0%) had been admitted to at least
one of the study hospitals in the year prior to first isola-
tion of ESBL. The overall 30-day all-cause mortality
from the date of culture positivity was 9.7% and the
1 year mortality was 61.4%.
A slight majority of samples were from hospital inpatients
(256, 55.4%) with LSF residents accounting for 26.2%
(n=67) of the hospital inpatients. Most of the hospital
inpatients who were residents of LSF (n=54) has been ad-
mitted to one of the study hospitals in the previous year. Of
the 233 hospital patients with admission data available,
ESBLs were cultured from 66 (28.3%) within 2 days of ad-
mission. Of the patients who cultured an ESBL more than
2 days after admission, the median period from admission
to ESBL culture was 16 days (3–801). Just under half
patients (44.6%) were from the community with LSF resi-
dents representing 34.5% of the 206 community patients. It
is important to note however 89 (43.2%) of the community
patients were not admitted to hospital in the previous year
and did not reside in a LSF.
At the beginning of April 2005 (end of third quarter)
the approach to screening for ESBL was changed from
the application of NCCLS criteria for ceftazidime and
cefotaxime to ampicillin-resistant Enterobacteriaceae to
universal testing for susceptibility to cefpodoxime using
the CLSI method. The number of ESBLs detected imme-
diately increased from 17 isolates (from all sites) in the
first 9 months before the change in method to 61 in the
next 9 month period. This step change in the second
quarter of 2005 is therefore related to a change in
method however the screening approach then remained
constant and the subsequent pattern is one of a progres-
sive increase in the number of ESBLs isolated per quar-
ter to a peak of 73 in the last quarter of 2008.
The percentage of ESBL E.coli isolated from urine and
blood per quarter were calculated to compare to na-
tional EARSS data (Figure 1). Duplicate samples were
removed from both the numerator and denominator
groups on a quarterly basis. E. coli ESBL bacteremias
increased from 1.6% of isolates in the first year of CLSI
ESBL detection (April 2005 to March 2006) to 5.4% in
the final 12 months of ESBL detection (January to De-
cember 2008). The national EARSS data showed an in-
crease from 2.8% to 5% for the corresponding time
periods. ESBL E. coli isolates from urine increased from
1.2% to 3.9% for the corresponding 12 months periods.
The quarterly rate for ESBL E. coli in urine and blood
cultures was compared to national EARSS data. The
mean prevalence of ESBL-producing E. coli from bacter-
emias was 3.8% which corresponded closely with the
EARSS rate of 3.4%. The linear regression was significant
for urine (R2 87.4%, p <0.001) but not for the blood cul-
tures (R2 11.6%, p > 0.1). This may be related to the rela-
tively low numbers of blood culture isolates.
The resistance of blood and urinary ESBL producing
E. coli to other antimicrobial agents was assessed
(Table 1). All blood culture isolates were resistant to
ciprofloxacin and susceptible to meropenem. Nitrofuran-
toin was the most consistently active non-betalactam
agent against ESBL isolates from urine. Changes in % re-
sistance over time were assessed for urine isolates. The %
resistance to nitrofurantoin changed very little (1.2% in-
crease) over the period studied. Other oral agents
showed a greater increase in resistance, with % resistance
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to ciprofloxacin and trimethoprim increasing by 14.4% and
29.3% respectively. The % resistance to amikacin showed a
5.2% increase and to gentamicin a 7.8% decrease.
Urine ESBL-producing E. coli isolates were divided based
on three patient categories, (1) those resident in the com-
munity (i.e. not in hospital or LSF) at time of isolation, (2)
hospitalised patients who did not normally reside in a LSF
and (3) residents of a LSF whether in hospital or in the LSF
at the time of isolation of ESBL. The merging of hospita-
lised and non hospitalised LSF patients was based on the
absence of significant differences between the data when
the groups were considered separately. As shown in Table 2,
the prevalence of antimicrobial co-resistance to non-
betalactams in urine ESBL E. coli shows a significantly in-
creasing trend in the prevalence of co-resistance from com-
munity to hospital to LSF patients for all antimicrobials
except for nitrofurantoin.
Data for a survival analysis were available for 464
patients of whom 124 had a known date of death and
the others for whom the survival time was censored at
the final study date. Overall the median survival time
was 488 days (from 0–1856 days). The median survival
time of the deceased patients was 76 days (0–926 days).
The 30 day all-cause mortality was 9.7%. A Cox regres-
sion analysis of the survival times of patients with an
ESBL infection was performed. Included risk factors
were age, gender, nursing home resident, E.coli ESBL
and a hospital admission in the year prior to the ESBL
isolation. The interpretation of the hazard ratio and 95%
Confidence Interval (CI) is similar to that for the odds
ratio. Hazard ratios of 1 mean the groups do not differ
in the time to death, a hazard ratio > 1 means that the
group of interest has a shorter time to death compared
to the reference group (i.e. this group is at ‘higher risk’
of death). Only factors with a p value of less than 0.05
were kept in the model. No interactions were significant.
Age, gender and previous hospital admission were sig-
nificant risk factors in the model. Being admitted to hos-
pital in the year prior to the isolation of the ESBL
increased the hazard ratio to 2.7 (95% CI 1.8-4.2). Being
male increased the hazard ratio to 2.3 (95% CI 1.6-3.3)
and for every year older the hazard ratio increased with
Table 1 Antimicrobial Resistance in ESBL-producing E. coli from Blood (N=15) and Urinary (N=366)
Susceptible (%) Intermediate (%) Resistant (%)
Blood Urine Blood Urine Blood Urine
Amikacin 11 (78.6) 312 (86.4) 2 (14) 29 (8.0) 1 (7.1) 20 (5.5)
Gentamicin 9 (60.0) 254 (70.2) 1 (7) 3 (0.8) 5 (33.3) 105 (29.0)
Ciprofloxacin 0 (0) 62 (17.0) 0 (0) 1 (0.3) 15 (100) 302 (82.7)
Meropenem 15 (100) - 0 (0) - 0 (0) -
Trimethoprim - 68 (18.6) - 0 (0) - 297 (81.4)
Nalidixic Acid - 43 (11.8) - 1 (0.3) - 319 (87.9)
Nitrofurantoin - 323 (88.5) - 20 (5.5) - 22 (6.0)
Legend to Table 1. Susceptibility, Intermediate and Resistance to non-beta-lactam antimicrobial agents by Clinical Laboratory Standards Institute criteria for ESBL
producing E. coli for the period July 2004 to December 2008. Note: one or more isolates had incomplete susceptibility data therefore the totals for each row do
not fully correspond.
Figure 1 ESBL E. coli as a percentage of E. coli isolated from blood and urine per quarter (July 2004 – December 2008). Horizontal axis
time line begins July 2004. Triangles represent % ESBL E. coli from blood in the study hospitals and circles represent the % ESBL E. coli from urine
per quarter. The dashed line and solid lines represent the respective linear trends for blood and urine. Solid black squares show national data for
ESBL E. coli from blood cultures per quarter from the European Antimicrobial Resistance Surveillance System.
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1.03 (1.01-1.04). When age was categorised into those
over and under 60, the hazard ratio was 2.4 (95% CI 1.4-
4.3) for the older group. Figures 2,3 and 4 show the sur-
vival plots for gender, previous hospitalisation and age
above and below 60.
Discussion
This work examined 4.5 years of clinical epidemiological
and laboratory data of ESBL cultures from all clinical
sites from 3 Irish hospitals. This is the first extensive in-
vestigation of the epidemiology of ESBL producing
Enterobacteriaceae from all specimen types in Ireland.
The broad trends are similar to that observed in other
countries. The predominance of female patients (65%)
and urine samples (84%) is consistent with previously
published studies[21-23]. The similar numbers of iso-
lates from the hospital setting (54%) and the community
setting (46%) confirms the extent to which ESBLs have
extended beyond the confines of the hospital into the
wider community. It is particularly important to note
that a high proportion (42%) of community isolates are
from people who do not live in nursing homes and had
no history of hospital admission in the previous year and
who therefore may not be identified as at risk for infec-
tion with antimicrobial resistant Enterobacteriaceae.
However it is a limitation of the study that some of these
patients may have been hospitalised elsewhere during
the previous year. This finding is however consistent with
a Spanish study which showed that almost half of the
community patients had no history of hospital admission
in the previous year and had not been in a LSF [23].
From a clinical perspective the data indicate that at
present meropenem remains a reliable agent for treat-
ment of ESBLs and amikacin is also active in most cases.
Nitrofurantoin is important in that it is active against
most ESBLs and there is no clear trend to increasing re-
sistance. We have not included data on beta-lactams
other than meropenem in the analysis however it is ap-
propriate to note that a significant number of isolates
are susceptible in vitro to coamoxiclav and piperacillin/
tazobactam. The role of these agents in therapy of ESBL
related infection has been the subject of much debate al-
though recently a consensus has emerged that with the
application of current interpretive criteria for beta-
lactams agents an in-vitro susceptible result may be
accepted clinically relevant (www.eucast.org).
The change in detection method from the application of
cefotaxime/ceftazidime screening criteria to ampicillin-
resistant isolates to the screening of all isolates with cefpo-
doxime in April 2004 resulted in a dramatic step increase
in the number of ESBLs detected. In Ireland as in other
countries, the extent of ESBL dissemination has most
likely been underestimated due to limited application of
appropriate detection methods in Irish laboratories as has
been shown in other countries [24]. Correct determination
Table 2 Antimicrobial resistance in ESBL E. coli from urine by residence and hospitalization status
Community Hospital inpatients LSF Total (% resistant) P value for trend
Amikacin, n (%) 4 (20.0) 5 (25.0) 11 (55.0) 20 (6.0) 0.033
Gentamicin, n(%) 26 (24.8) 34 (32.4) 45 (42.9) 105 (29.2) 0.002
Ciprofloxacin, n (%) 89 (29.5) 101 (33.4) 112 (21.9) 302 (83.0) 0.000
Trimethoprim, n (%) 98 (33.0) 93 (31.3) 61 (35.7) 297 (81.4) 0.006
Nalidixic Acid, n (%) 102 (32.0) 104 (32.6) 113 (35.4) 319 (88.1) 0.000
Nitrofurantoin, n (%) 8 (36.4) 4 (18.2) 10 (45.5) 22 (6.4) n.s.
Legend to Table 2. The prevalence of ESBL E. coli (%) resistant to non beta-lactam antimicrobial agents by patient status. Community means those resident in the
community at time of isolation, hospitalised means hospitalised patients who normally reside in the community and LSF refers to residents of a LSF whether in
hospital or in the LSF at the time of isolation of ESBL E. coli. P values indicate the significance of a trend of increasing prevalence of resistance from the
community population through to the patient population resident in an LSF. Note comparison of data for hospitalised and non-hospitalised LSF patients showed
no significant difference.
Figure 2 Survival plot by gender of patients from whom ESBLs
were isolated. Legend to Figure 2. Cumulative survival of patients
from whom ESBLs were isolated by gender. The upper (green) line is
female, the lower blue line is male.
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of the mechanism of beta-lactam resistance may be less
important in the future for clinical purposes as newer,
lower breakpoint criteria from CLSI and EUCAST are
likely to be more effective at differentiating between those
isolates that are likely to respond to therapy and those
which will not. Nevertheless detection of the mechanism
remains important for epidemiological and infection con-
trol purposes and this paper underlines the importance of
comprehensive testing for novel resistance mechanisms in
isolates from a broad range of specimen types from hos-
pital and community may have particular relevance to
monitoring the current emergence of carbapenemase pro-
ducing Enterobacteriaceae.
Our assessment shows an increase in the percentage of
ESBL-producing E. coli from both blood and urine iso-
lates over the time period studied and this had reached
9.0% and 4.7% respectively by the end of the study. In
2009 this trend continued and 5% of urine E. coli isolates
and 11.9% of blood culture E. coli isolates were ESBL
producers. These trends closely parallel the results seen
in the Irish EARSS data. This indicates that the EARSS
data are a useful barometer of antimicrobial resistance
trends in clinical E. coli isolates other than blood. The
principle limitation of EARSS data is that by the nature
of blood stream infection it tends to focus on those hos-
pitalised with serious illness and therefore is not sensi-
tive to trends in the community.
Residence in a nursing home is widely recognised as a
risk factor for acquisition for ESBLs and we and others
have published evidence of transfer of isolates between
nursing home residents [18,25]. However the finding
that ESBL isolates from residents of nursing homes are
associated with higher levels of co-resistance to other
classes of antimicrobial agents, in particular higher levels
of co-resistance than observed in ESBL isolates from
hospital patients (other than those admitted from nurs-
ing homes) was unexpected. This suggests that nursing
homes may play an important part in amplification and
dissemination of multiply-resistant ESBLs. Characterisa-
tion of ESBLs to determine relationships at a molecular
level and define the specific genetic basis of resistance
was not undertaken in this study.
Mortality
The data indicate that in patients from whom ESBLs
have been isolated overall 30 day all-cause mortality was
9.7% and that male sex, increasing age and previous hos-
pital admission were independently associated with
higher mortality. The same risk factors were shown to be
associated with community ESBL infections by Ben-Ami
et al. [26]. The clear association of age with mortality
would be expected in the light of increasing morbidity
with age. Urinary tract infections in males are generally
less common and associated with anatomical abnormal-
ities and therefore males in this study may represent a
Figure 3 Survival plot by history of hospitalisation in the year
prior to isolation of ESBL. Legend to Figure 3. Cumulative survival
of patients from whom ESBLs were isolated by history or hospital
admission in the year prior to isolation of ESBL. The upper (blue)
represents survival of those without history of admission, the lower
(green) represents survival of those with a history or hospitalisation.
Figure 4 Survival plot for patients from whom ESBLs were
isolated by age over or under 60 years of age. Legend to
Figure 4. Cumulative survival of patients from whom ESBLs were
isolated by age over and under 60 years. The upper (blue) line
represents survival of those under 60, the lower (green) line
represents survival of those over 60.
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cohort of individuals with significant comorbidity related
to prostatic obstruction and other factors. This may ex-
plain the increased mortality of males compared to
females.
This study has a number of limitations. There was lim-
ited clinical data, no data on antimicrobial exposure and
no control group. Details of co-morbidities and risk fac-
tors such as diabetes mellitus, liver disease, malignancy,
renal dysfunction, presence of long term urinary cathe-
ters or inadequate empirical therapy are absent. As we
did not have access to all databases of all hospitals it is
possible that some patients were misclassified with re-
spect to hospital admission in the previous year. Never-
theless we believe the data contribute to improved
understanding of the epidemiology of ESBL transmission
and in particular the extent to which ESBLs are now
common even in those with no apparent prior engage-
ment with the health care services. Reducing and opti-
mising antimicrobial use across all sectors is accepted as a
key intervention to limit the spread of acquired antimicro-
bial-resistance. A 2008 report examining antimicrobial con-
sumption in Irish Acute hospitals (http://www.hpsc.ie/
hpsc/A-Z/MicrobiologyAntimicrobialResistance/European-
SurveillanceofAntimicrobialConsumptionESAC/Surveillan-
ceReports/File,3889,en.pdf) demonstrated relatively high
levels of antimicrobial consumption in Irish hospitals.
Community antibiotic prescribing data was not readily
available but Ireland was reported as one of only 3 Euro-
pean countries where community prescriptions were in-
creasing[27]. There is clearly much work to be done to
improve standards of antimicrobial stewardship.
The particular association of high levels of co-
resistance to other classes of antimicrobial agents with
isolates from residents of nursing homes is of concern.
The extent to which it is possible to limit spread of
antimicrobial-resistant Enterobacteriaceae in nursing
homes is questionable. It is generally not practical in a
nursing home to achieve the standards of infection con-
trol practice that are expected in an acute care setting. It
would almost certainly not be possible to maintain the
extent of patient segregation that is common in acute
hospitals. Furthermore antimicrobial consumption in
nursing homes is likely to be difficult to restrict. Sup-
porting older people to continue to live in their own
communities may be the most effective approach to
addressing this problem in addition to the many other
benefits associated with maintaining independent living
for as long as possible.
Conclusions
This study was the first extensive epidemiological assess-
ment of Irish ESBL-producing isolates and reveals their
increasing prevalence in community, hospital and long
stay patients and gives a preliminary assessment of the
associated mortality. The finding that ESBL isolates from
residents of nursing homes are associated with higher
levels of co-resistance to other classes of antimicrobial
agents, in particular higher levels of co-resistance than
isolates from hospital patients not admitted from nurs-
ing homes was unexpected and worrying. This suggests
that nursing homes may play an important part in amp-
lification and dissemination of multiply-resistant ESBLs.
The data should help improve clinical and public health
awareness of this issue and aid development of local em-
piric antimicrobial regimens for community acquired
bloodstream and urinary tract infections.
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